ETF Evaluator:
WisdomTree BioRevolution ETF ()
Follow This ETF
(as of Aug 26)
Best Performing in Health Over the Last Year
| 129.4% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 94.1% | ALPS Medical Breakthroughs ETF (SBIO) |
| 88.4% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 72.5% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 65.8% | State Street® SPDR® S&P® PhrmctlsETF (XPH) |
Risk
Index
Risk
Index
ETF Details
WisdomTree BioRevolution ETF Overview
WisdomTree BioRevolution ETF (WDNA) is a passively managed Sector Equity Health exchange-traded fund (ETF). WisdomTree launched the ETF in 2021.
The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”).
The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
About WisdomTree BioRevolution ETF (WDNA)
There are 5 members of the management team with an average tenure of 5.11 years: Marlene Walker-Smith (2021), David France (2021), Todd Frysinger (2021), Vlasta Sheremeta (2021) and Michael Stoll (2021). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 2 primary benchmarks: S&P 500 Equal Weighted TR USD index with a weighting of 100% and WisdomTree BioRevolution USD index with a weighting of 100%. WisdomTree BioRevolution ETF has 86 securities in its portfolio. The top 10 holdings constitute 30.9% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
WisdomTree BioRevolution ETF is part of the Equity global asset class and is within the Sector Equity ETF group. WisdomTree BioRevolution ETF has 14.3% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 85.6% There is 14.3% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). WisdomTree BioRevolution ETF has 0.1% of the portfolio in cash.
Assets Under Management
The fund has $2 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
WDNA Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The WisdomTree BioRevolution ETF expense ratio is average compared to funds in the Health category. WisdomTree BioRevolution ETF has an expense ratio of 0.45%, which is 13% lower than its category average, making the fund expense ratio grade a C. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. WisdomTree BioRevolution ETF has a portfolio turnover rate of 32%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 45% for the Health category.
Recently, in the month of July 2026, WisdomTree BioRevolution ETF returned -5.8%, which earned it a grade of F, as the Health category had an average return of -0.1%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
WisdomTree BioRevolution ETF has a trailing yield of 3.97%, which is above the 1.10% category average.
The fund normally distributes its income annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
WisdomTree BioRevolution ETF Grades
Year to date, the ETF has returned 14.7%, 5.0 percentage points better than the category, which translates into a grade of B. The fund has returned 46.8% over the past year (grade of B), 3.8% over the past three years (grade of D) and -4.4% per year over the past five years (grade of F).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about WisdomTree BioRevolution ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
WDNA Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| WDNA Return (NAV) | -5.8% | 9.2% | 46.8% | 3.8% | -4.4% | na |
| WDNA Return (Price) | -3.3% | 11.7% | 50.1% | 4.8% | -3.9% | na |
| NAV +/- Price Return | -2.452% | -2.561% | -3.368% | -0.958% | -0.467% | na |
| Health Avg | -0.1% | 11.2% | 36.9% | 9.9% | 1.6% | 8.7% |
| WDNA Grade (NAV) | F | D | B | D | F | na |
| +/- Category (NAV) | -5.7% | -2.1% | 9.9% | -6.1% | -6.0% | na |
| WDNA Tax-Cost Ratio | na | na | 1.6% | 0.7% | 0.4% | na |
WDNA Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| WDNA Return (NAV) | 14.7% | 22.9% | -14.1% | -2.3% | -26.1% | na | na | na | na | na | na |
| WDNA Return (Price) | 18.0% | 22.7% | -14.2% | -2.1% | -26.3% | na | na | na | na | na | na |
| NAV +/- Price Ret | 0.221% | -0.009% | 0.005% | -0.092% | 0.009% | na | na | na | na | na | na |
| Health Avg | 9.7% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| WDNA Grade (NAV) | B | C | F | D | D | na | na | na | na | na | na |
| +/- Category | 5.0% | 1.2% | -14.2% | -4.5% | -9.8% | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | 1.26 |
| R-Squared: | 41% |
| Standard Deviation: | 24.8% |
| Category Risk Index: | 1.23 |
| Category Risk Rating: | High |
| Total Risk Index: | 2.02 |
| Total Risk Rating: | High |
| Portfolio Characteristics | |
| Yield: | 4.0% |
| Total Assets: | $ 3 Mil |
| Share Class Assets: | $ 3 Mil |
| Turnover: | 32.0% |
| Expense Ratio: | 0.45% |
| Index Fund: | Yes |
| Index Tracked: | S&P 500 Equal Weighted TR USD |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 5 | |||
| Longest Tenure: 5.2 years | |||
| Average Tenure: 5.1 years | |||
| Managers (Year): Walker-Smith Marlene (2021), France David (2021), Frysinger Todd (2021), Sheremeta Vlasta (2021), Stoll Michael (2021) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 86 |
| % in Top 10 Holdings: | 30.9% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 14.3% |
Portfolio Allocation |
|
| Domestic Stock: | 85.6% |
| Foreign Stock: | 14.3% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | WisdomTree |
| Phone Number: | 866-909-9473 |
| Website: | www.wisdomtree.com |
| Inception Date: | June 1, 2021 |
Expenses and Fees
| Expense Ratio (%): | 0.45% (Rating: Avg) |
| Category Average Expense Ratio (%): | 0.52% |
